|Bid||4.69 x 800|
|Ask||4.69 x 1100|
|Day's Range||4.39 - 4.72|
|52 Week Range||3.30 - 29.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 32.35% and 13.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 62.16% and 55.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.
In the wake of recently revealed abstracts from the 2018 ASCO meeting, Jounce therapeutics (NASDAQ:JNCE) stock price recently took a significant haircut, but was the drop justified? The goal of the therapy is to tip the balance between these two subtypes of T-cells towards the effector cells by depleting T-regs through antibody activity (ADCC) and encouraging growth of T-effector cells which express ICOS.
Wells Fargo Securities analyst Jim Birchenough downgraded Jounce from Outperform to Market Perform and lowered the price target from $37 to $13. The overall response rate for JTX-2011 as a monotherapy in gastric cancer and triple negative breast cancer, and for the JTX-2011-Opdivo combo in gastric cancer and TNBC, is underwhelming, Birchenough said in a Thursday note.
Shares of Jounce Therapeutics and Sangamo Therapeutics were both hit hard last week by the marketwide sell-off. This dip is likely to prove temporary in both cases, however.
Bioverativ Inc (NASDAQ:BIVV), spun out of Biogen Inc. (NASDAQ:BIIB) less than a year ago, drew an $11.6 billion bid from Sanofi SA (ADR) (NYSE:SNY) on Jan. 22, a 64% premium over its closing price on Jan. 19. The bid, $105 per share, could be just the start of a shopping bonanza as big pharma companies seek to grow their drug pipelines through acquisitions of smaller biotech companies.
For the biotech superstar, Celgene Corporation (NASDAQ:CELG), the last few months have not been too kind. CELG stock has hit a rough patch on several different fronts. That included it stopping phase 3 clinical trials for a potential blockbuster for Crohn’s disease as well as reducing forward earnings forecasts based on that stoppage and the fact that Revolve won’t be coming to market.
The company’s lead asset, Trilaciclib, is currently being evaluated in a number of settings as a tack-on to the standard of care in both front line and 2nd-3rd lines of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). CDK4/6 keeps cells in stasis, known as the G1 phase of the cell cycle, rendering it difficult to undergo cell division.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Jounce Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Jounce Therapeutics, Inc. a score of 65. Our analysis is based on comparing Jounce Therapeutics, Inc. with the following peers – Neurocrine Biosciences, Inc., NantKwest, Inc., Molecular Templates, Inc. and Momenta Pharmaceuticals, Inc. (NBIX-US, NK-US, MTEM-US and MNTA-US). Investment Outlook Jounce Therapeutics, Inc. has a fundamental score ... Read more (Read more...)